Related Experiment Video
Updated: Apr 15, 2026
04:37
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
1.3K
Summary
Patients with heparin-induced thrombocytopenia and thrombosis (HIT) who are homozygous for arginine at position 131 in the IgG receptor FcγRIIA show a higher thrombosis incidence. Plasma IgG may modulate the thrombotic process in these patients.
Area of Science:
- Immunology
- Hematology
- Thrombosis Research
Background:
- Heparin-induced thrombocytopenia and thrombosis (HIT) is a serious immune-mediated complication of heparin therapy.
- The FcγRIIA receptor plays a role in immune complex-mediated thrombosis.
- Genetic variations in FcγRIIA may influence HIT susceptibility and severity.
Purpose of the Study:
- To investigate the association between FcγRIIA genotype and thrombosis risk in HIT patients.
- To explore the role of plasma IgG in modulating thrombotic events in HIT.
Main Methods:
- Genotyping of FcγRIIA receptor polymorphisms in HIT patients.
- Analysis of thrombosis incidence based on FcγRIIA genotype (arginine homozygous vs. others).
- Measurement of plasma IgG levels and their correlation with thrombotic events.
Main Results:
- HIT patients homozygous for arginine (R) at position 131 in FcγRIIA exhibited a significantly higher incidence of thrombosis.
- Plasma IgG levels were found to correlate with the thrombotic process, suggesting a modulatory role.
Conclusions:
- The FcγRIIA receptor genotype, specifically homozygosity for arginine at position 131, is a significant risk factor for thrombosis in HIT patients.
- Plasma IgG appears to play a crucial role in the pathogenesis and modulation of thrombosis in HIT.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:24Disorders of Hemostasis
2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
01:29Venous Thrombosis III: Interprofessional Care
471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
01:30Venous Thrombosis I: Introduction
724
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
724
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.8K